Grace Therapeutics, Inc.
GRCE· Nasdaq
GRCEGrace Therapeutics, Inc.
Filed Aug 11, 2023 · 10-Q · 42 days after period end · 0000950170-23-041595
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$4.02M | -$4.52M | -$3.12M | -$4.67M |
| EPS Diluted | -$0.54 | -$0.61 | -$0.12 | -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 11, 2023 · 42 d after period end
